IP Library Granted Patent US 12,629,386
Granted Patent B2
US 12,629,386 · App. 17/903,208 · Granted May 19, 2026

Omega-3 compositions

Inventors: Nils Hoem (Oslo, NO); Lena Burri (Oslo, NO); Kjetil Berge (Oslo, NO)
Assignee: Aker BioMarine Human Ingredients AS
A61K31/685A61K9/4858
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,629,386
App. No.
17/903,208
Granted
May 19, 2026
Kind
B2
Abstract

The present invention relates to compositions comprising omega-3 fatty acid derivatives, and in particular to compositions comprising omega-3 phospholipids in combination with other omega-3 derivatives.

Claims (21)

1 . A composition comprising:

a) a mixture of krill phospholipid compounds having the following structure:

wherein R1 and R2 are selected from the group consisting of a fatty acid moiety and H and wherein at least 30% w/w of the fatty acid moieties at positions R1 and R2 are omega-3 fatty acid moieties, and R3 is H or a choline, ethanolamine, inositol and serine moiety, said mixture of krill phospholipid compounds comprising more than about 90% choline moieties at position R3; and

b) a mixture of omega-3 fatty acid derivatives selected from the group consisting of:

a mixture of glyceride compounds having the following structure:

wherein at least one of either R1, R2, and R3 is an omega-3 fatty acid moiety,

and the other two of either R1, R2 and R3 may be H or a fatty acid moiety,

and esters and free fatty acids of omega-3 fatty acids, and combinations thereof;

wherein said composition comprises from 20% to 60% w/w of said krill phospholipid compounds, at least 10% of said glyceride compounds, and at least 10% w/w ethyl esters comprising said omega-3 fatty acid moieties so that the composition comprises from 20% to 65% w/w of said omega-3 fatty acid moieties in total;

wherein said omega-3 fatty acid moieties or free fatty acids are selected from the group consisting of eicosapentaenoic acid and docosahexaenoic acid and combinations thereof,

wherein said composition is an oil.

2 . The composition of claim 1 , wherein said omega-3 moieties in said mixture of krill phospholipid compounds are eicosapentaenoic acid and said docosahexaenoic acid and wherein said eicosapentaenoic acid and said docosahexaenoic acid are present in a ratio of eicosapentaenoic acid:docosahexaenoic acid of from about 1:1 to about 3:1.

3 . The composition of claim 1 , wherein said composition comprises at least 20% w/w ethyl esters comprising said omega-3 fatty acid moieties.

4 . The composition of claim 1 , wherein said composition comprises at least 10% w/w glyceride compounds comprising said omega-3 fatty acid moieties.

5 . The composition of claim 1 , wherein said composition comprises at least 10% w/w omega-3 free fatty acids.

6 . The composition claim 1 , wherein said composition comprises astaxanthin.

7 . The composition claim 6 , wherein said composition comprises at least a second antioxidant in addition to the astaxanthin.

8 . The composition of claim 1 , wherein said composition is provided in a formulation selected from the group consisting of a capsule, a dietary supplement, a nutritional supplement, a beverage and a functional food.

9 . The composition of claim 1 for use in reducing serum triglycerides, reducing serum cholesterol, reducing plaque formation, reducing platelet aggregation, treating atherosclerosis, improving cardiovascular health, reducing inflammation, reducing coronary heart disease, treating depression, treating Alzheimer's disease, treating attention deficit disorder, or treating metabolic syndrome, by oral or intravenous administration to a subject selected from the group consisting of humans, non-human primates, domestic raised or farmed animals, and companion animals.

10 . The composition of claim 9 , wherein said composition is administered in a daily dose of from about 0.1 to about 3 grams.

11 . The composition of claim 1 , wherein said eicosapentaenoic acid and said docosahexaenoic acid are present in a ratio of eicosapentaenoic acid:docosahexaenoic acid of from about 1:1 to about 3:1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2024
From: AKER BIOMARINE ANTARCTIC AS
To: AKER BIOMARINE HUMAN INGREDIENTS AS
Reel/Frame 066703/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2022
From: HOEM, NILS; BURRI, LENA; BERGE, KJETIL
To: AKER BIOMARINE ANTARCTIC AS
Reel/Frame 061209/0392 →
Continuity (6)
Continuation 16165100 · Oct 19, 2018
Continuation 14035167 · Sep 24, 2013
Provisional Application 61775032 · Mar 8, 2013
Provisional Application 61739260 · Dec 19, 2012
Provisional Application 61704854 · Sep 24, 2012
Related Publication 20230011876A1 · Jan 12, 2023
References Cited (24)
US 5656557A · Hata · 1997 [cited by examiner]
US 5656667A · Breivik · 1997 [cited by applicant]
US 6800229B2 · Acerbi · 2004 [cited by examiner]
US 6800299B1 · Beaudoin · 2004 [cited by examiner]
US 10105376B2 · Hoem · 2018 [cited by examiner]
US 20080274203A1 · Bruheim · 2008 [cited by examiner]
US 20100239715A1 · Beaudoin · 2010 [cited by examiner]
US 20110223246A1 · Opheim · 2011 [cited by applicant]
WO 0023546 · 2000 [cited by applicant]
WO 0048592 · 2000 [cited by applicant]
WO WO0048592A1 · 2000 [cited by examiner]
WO 2006054183 · 2006 [cited by applicant]
WO 2007088421 · 2007 [cited by applicant]
WO 2008060163 · 2008 [cited by applicant]
WO 2008117062 · 2008 [cited by applicant]
WO 2009139641 · 2009 [cited by applicant]
WO WO2010097699A1 · 2010 [cited by examiner]
WO WO2010097701A1 · 2010 [cited by examiner]
Grupp, et al., Protection against Hypoxia-reoxygenation in the Absence of Poly (ADP-ribose) Synthetase in Isolated Working Hearts, J. Mol. Cell. Cardio. 31: 297-303 (1999). [cited by applicant]
Steffens, W. Effects of variation in essential fatty acids in fish feeds on nutritive value of freshwater fish for humans, Aquaculture vol. 151, pp. 97-119, published 1997. [cited by applicant]
Fatty Acid Composition of Fish Oils: United States Department of Interior Fish and Wildlife Service Bureau of Commercial Fisheries. Published 1965. [cited by applicant]
Armenta, J. Am. Oil Chem. Soc. vol. 84 pp. 1045-1052, 2007. [cited by applicant]
Kolakowsaka, Journal of Food Science, vol. 59, pp. 88-90, published 1994. [cited by applicant]
Schuchardt, Lipids in Health and Disease, vol. 10—pp. 145 pp. 1-7, published 2011. [cited by applicant]